Troponin I (Recombinant)

Added to your cart

Troponin I (Recombinant)

Cart subtotal: £0.00

View cart (0) Checkout

#SKU P725-3


Price excludes shipping costs.
To view our shipping costs click here.

Not all of our products can be shipped to all countries. If you're experiencing issues, please contact our customer service team.

Need to order this product in bulk?

Contact our team of experts to discuss your bulk requirements

Contact our expert team

Product Details

Troponin I is the flexible conformationally adaptive part of the Troponin complex interacting with both TnC and TnT, as well as with actin in cardiac muscle. cTnI is the only isoform present in the adult heart and it does not switch under pathological conditions and is released following cardomyosyte stress. Along with Troponin T the levels of Troponin I have been shown, using monoclonal antibodies to specific regions to be diagnostic for myocardial infarction and useful in stratification of cardiac disease.


More information



  • Shipping Information
  • Dry Ice
  • Abbreviations
  • Trop I
  • Specification
  • >96%
  • Recommended Use
  • Research and further manufacturing
  • Storage
  • Below -15°C
  • Buffer
  • 50mM Tris, 6M urea pH 8.0
  • Presentation Matrix
  • 50mM Tris, 6M urea pH 8.0
  • Purity/grade
  • >96%
  • Source
  • Expressed in E.coli
  • Molecular weight
  • ~24kDa
  • Uniprot No.
  • P19429

Technical Documents

Certificates Of Analysis (107.74KB)

Sorry, no results found.

Enter the full lot number and hit enter.

BBI Solutions Brands


The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.


Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.


Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox